Aspire BioPharma is trading at $8.70, up +5.33% on August 28, 2026, after rising from the August 27 close of $8.26.
- No clear company-specific announcement dated August 28 was identified; the latest filings and reported developments concern the August 19 investor conference and August 10 Dura acquisition.
- The broader biotech sector is declining, so sector weakness does not explain this contrary-direction gain.